Health

Explainer

Updated

What is potassium iodide for?

Key facts

The FDA says potassium iodide (KI) blocks only radioactive iodine from reaching the thyroid, and sets out its doses by age group in its own table.

The FDA says that potassium iodide (KI) works only to prevent radioactive iodine from being taken up by the thyroid gland, and that it "is not a general radioprotective agent." The Nuclear Regulatory Commission (NRC) says that, if taken properly, KI may reduce how much radioactive iodine the thyroid gland is able to absorb. This page sets out what the two agencies say and adds no advice of its own.

What KI does and does not do

The FDA says KI "floods the thyroid with non-radioactive iodine and prevents the uptake of the radioactive molecules, which are subsequently excreted in the urine." The table sets out what the FDA's answers say KI does and does not do.

What the FDA says KI doesWhat the FDA says KI does not do
Reduces the uptake of radioactive iodine into the thyroid glandProtect against radiation from bombs other than radioactive iodine, such as a dirty bomb
Reduces the risk of thyroid cancer when given in the recommended dose to people at risk from inhaling or ingesting radioiodinesServe as a preventative taken before radiation exposure, which the FDA says it should not be
Is available without a prescriptionReplace the instructions of local officials, who say whether to take it after an event in the United States

Who the FDA says needs it most

The FDA says its guidance prioritizes groups by age, because age is the primary factor for risk of radioiodine-induced thyroid cancer. It says infants and children, and pregnant and nursing females, are at highest risk, because KI can suppress thyroid function in a developing fetus and a newborn, and that they should be treated at the lowest threshold. It says anyone over 18 and up to 40 should be treated at a slightly higher threshold, and that anyone over 40 should be treated with KI only if the predicted exposure is high enough to destroy the thyroid and induce lifelong hypothyroidism.

Dosing by age group

The FDA lists a threshold for each risk group, the predicted thyroid gland exposure in centigrays (cGy) at which it recommends KI, with the dose for that group. Its full table has more columns than fit on this page, so the numbers are shown in two tables, both copied from the FDA.

Risk groupPredicted thyroid gland exposure (cGy)KI dose (mg)
Adults over 40 years> 500130
Adults over 18 through 40 years> 10130
Pregnant or lactating women> 5130
Adolescents, 12 through 18 years> 565
Children over 3 years through 12 years> 565
Children over 1 month through 3 years> 532
Infants birth through 1 month> 516
Risk groupTabletsOral solution (65 mg per mL)
Adults over 40 years1 tablet (130 mg) or 2 tablets (65 mg)2 mL
Adults over 18 through 40 years1 tablet (130 mg) or 2 tablets (65 mg)2 mL
Pregnant or lactating women1 tablet (130 mg) or 2 tablets (65 mg)2 mL
Adolescents, 12 through 18 years½ tablet (130 mg) or 1 tablet (65 mg)1 mL
Children over 3 years through 12 years½ tablet (130 mg) or 1 tablet (65 mg)1 mL
Children over 1 month through 3 years130 mg: use KI oral solution. 65 mg: ½ tablet0.5 mL
Infants birth through 1 month130 mg and 65 mg: use KI oral solution0.25 mL

The FDA says adolescents approaching adult size (over 150 lbs or over 70 kg) should receive the full adult dose of 130 mg. It says its oral solution is supplied in 1 oz (30 mL) bottles with a dropper marked for 1, 0.5 and 0.25 mL, and that each mL contains 65 mg of potassium iodide.

When to take it and for how long

The FDA says KI should not be taken as a preventative before radiation exposure. It says that after a radiological or nuclear event in the United States, local public health or emergency management officials will tell the public whether there is a need to take KI or other protective actions, and that people should follow the instructions those authorities give.

The FDA says KI works best if used within 3 to 4 hours of exposure, and that since it protects for approximately 24 hours, it should be dosed daily until the risk no longer exists. For pregnant females and neonates, it says priority for evacuation and sheltering should be given because KI can suppress thyroid function in the fetus and neonate, and that it does not recommend repeat dosing for them unless other protective measures are not available.

The FDA also says that taking a higher dose of KI, or taking KI more often than recommended, "does not offer more protection and can cause severe illness or death."

Who should not take it, or should use it with care

The FDA says persons with known iodine sensitivity should avoid KI, as should people with dermatitis herpetiformis and hypocomplementemic vasculitis, which are extremely rare conditions linked to an increased risk of iodine hypersensitivity. It says a seafood or shellfish allergy does not necessarily mean a person is allergic or hypersensitive to iodine.

According to the FDA, people with a nodular thyroid and heart disease should not take KI. People with multinodular goiter, Graves' disease and autoimmune thyroiditis should be treated with caution, especially if dosing goes on for more than a few days. The FDA says that if you are not sure whether you should take KI, you should consult your health care professional.

Side effects

The FDA lists these possible side effects: skin rashes, swelling of the salivary glands, and "iodism," which it describes as a metallic taste, burning mouth and throat, sore teeth and gums, symptoms of a head cold, and sometimes upset stomach and diarrhea.

Buying and availability

The FDA says only FDA-approved KI products may be legally marketed in the United States. As of March 2022, it listed these as approved and available without a prescription: iOSAT tablets, 130 mg, and iOSAT tablets, 65 mg, from Anbex, Inc.; ThyroSafe tablets, 65 mg, from BTG INTERNATIONAL, Inc.; and Potassium Iodide Oral Solution USP, 65 mg/mL, from Mission Pharmacal Company.

The NRC says its regulations require States, including tribal governments, that have populations in the 10-mile emergency planning zone of a commercial nuclear power plant to consider including KI in their emergency plans as a protective measure. It says KI may be recommended by States as a supplement to evacuation or sheltering in place, and that supplemental KI is not recommended for populations outside the 10-mile zone but within the 50-mile ingestion pathway zone.

What the guidance is and when it was updated

The FDA says it issued its final guidance on potassium iodide as a thyroid blocking agent in radiation emergencies in December 2001, and that this guidance updates its 1982 recommendations. It says adoption and implementation of the recommendations are at the discretion of the state and local governments responsible for regional emergency-response plans. The FAQ page is marked as current as of March 24, 2022.

The NRC's page was last reviewed and updated on August 27, 2026.

Have another question?